Premenstrual Syndrome Market Size 2024-2030: Bayer AG, Pfizer Inc., Zydus Cadila, Alkem Laboratories Ltd., Kobayashi Pharmaceutical Co., Ltd., Haleon Group of Companies

According to MarkNtel Advisors study the Global Premenstrual Syndrome Treatment Market is estimated to grow at a CAGR of around 3.7% during the forecast period, i.e., 2024-30.

Access Free Sample Report - https://www.marknteladvisors.com/query/request-sample/premenstrual-syndrome-treatment-market.html

Key Findings of the Study: Premenstrual Syndrome market

Global Premenstrual Syndrome Treatment Market Driver:

Growing Instances of Premenstrual Dysphoric Disorder (PMDD) Driving Market Growth – Globally, the instances of PMDD emerged as one of the major market drivers, which has been growing significantly, which is in particular due to the growing fitness issues among women. PMDD is the greater extreme shape of premenstrual syndrome, which often results in excessive bodily abnormalities, like belly pain, weight pain, swelling of breasts, and so forth. Also, the predominant aspect besides PMDD is intense hormonal balance, which is frequently related to the genetics of women. Further, consistent stress and other neurological conditions may also affect the hormonal balance among women, leading to PMDD. Henceforth, as the instances of PMDD have been escalating, the demand for treatment solutions has also amplified, which has been driving the market growth. This demand is also expected to grow in the forecast years, as the instance of PMDD would increase further.

Global Premenstrual Syndrome Treatment Market Challenge:

Lack of Awareness & Challenges in Diagnostics – PMS is often challenging to diagnose, because of the unavailability of specific signs and symptoms, which are related to PMS only. This often poses challenges to the physical diagnosis of PMS. Moreover, there is also an unavailability of a specific diagnostic tool or methodology for the identification of PMS. Hence, their diagnosis often remains limited in comparison to other diseases.

Further, another fundamental challenge to the market growth is the lack of awareness among women regarding the effects and symptoms of PMS. Lack of cognizance is generally prominent among women living in remote areas, who are normally uneducated and lack know-how of the signs of PMS. Hence, with a lack of knowledge, and restricted treatment alternatives, women are mostly unaware of the fact that they have PMS. This often affects the demand for PMS treatment solutions negatively in the market and has been one of the major challenges for market growth. This challenge would continue to persist in upcoming years as well if governments across different countries do not focus on improving awareness regarding the PMS among women.

For more detailed information about the Premenstrual Syndrome market report, click here – https://www.marknteladvisors.com/research-library/premenstrual-syndrome-treatment-market.html

Scope of the Report and Premenstrual Syndrome Market Segmentation:

By Drug Type

• Analgesics- Market Size & Forecast 2019-2030, USD Million
• Antidepressants- Market Size & Forecast 2019-2030, USD Million
• Oral Contraceptives- Market Size & Forecast 2019-2030, USD Million
• Ovarian Suppression Agents- Market Size & Forecast 2019-2030, USD Million
• Others (Diuretics, Herbal Supplements, etc.)- Market Size & Forecast 2019-2030, USD Million

By Type

• Prescription- Market Size & Forecast 2019-2030, USD Million
• Over-the-Counter (OTC)- Market Size & Forecast 2019-2030, USD Million

By Distribution Channel

• Hospital Pharmacies- Market Size & Forecast 2019-2030, USD Million
• Retail Pharmacies- Market Size & Forecast 2019-2030, USD Million
• Online Pharmacies- Market Size & Forecast 2019-2030, USD Million)

Among them, the Online Pharmacies segment held a giant share in the Global Premenstrual Syndrome Treatment Market.

Premenstrual Syndrome Market Development:

• 2022: Lupin received the US Food and Drug Administration approval for the generic oral contraceptive pill Drospirenone.

Geographical Analysis:

By Region

• North America
• South America
• Europe
• The Middle East & Africa
• Asia-Pacific

North America has been experiencing substantial growth in the Premenstrual Syndrome Treatment Industry in the past few years.

Note: If you require specific information not covered in the current report, we can provide it through customized option

Why choose Us?

MarkNtel Advisors is a leading consulting, data analytics, and market research firm that provides an extensive range of strategic reports on diverse industry verticals. We being a qualitative & quantitative research company, strive to deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, and individuals, among others.

For Media Inquiries, Please Contact:

Call: +1 628 895 8081 | +91 120 4278433

Email: sales@marknteladvisors.com

Sales Office: 564 Prospect St, B9, New Haven, Connecticut, USA-06511

Corporate Office: Office No.109, H-159, Sector 63, Noida, Uttar Pradesh-201301, India